Status: Recruiting
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine
Participants needed: 1,123
Trial details
Phase: Phase 2, Phase 3Age: 19-55Biological sex: AllType: InterventionalSponsor: EyeGene Inc.Updated: Dec 1, 2025Locations: 1
Eligibility criteria
Healthy males and females aged 19 to 55 years. [+2]
History of prior disease caused by N. meningitidis. [+23]